Tirzepatide is a dual GIP/GLP-1 receptor agonist. GIP (gastric inhibitory polypeptide) and GLP-1 are incretin hormones that have complementary roles in regulating insulin secretion and appetite.
By activating these receptors, Tirzepatide enhances insulin sensitivity, suppresses appetite, and slows down gastric emptying, contributing to weight loss.
**Weight Loss Efficacy: **
Tirzepatide has shown remarkable results in clinical trials for weight loss, often surpassing those seen with existing medications, including semaglutide.
While primarily investigated for type 2 diabetes, its potent weight loss effects have made it a candidate for obesity treatment, pending further regulatory approval for this specific indication.